Cybrexa Therapeutics Appoints Vishwas Paralkar, Ph.D. as Chief Scientific Officer

Share Article

Dr. Paralkar will lead the drug development effort for Cybrexa’s tumor targeting technology.

News Image
We are very pleased to have Vishwas join our team. We are confident that his leadership and breadth of drug development experience will enable us to move our technology from the research stage into the clinic.

Cybrexa Therapeutics, a start-up cancer therapeutics company, announced today that it has appointed Vishwas Paralkar to the role of chief scientific officer. In this role, Dr. Paralkar will lead the development of Cybrexa’s tumor targeting technology. He will report to Cybrexa’s president and CEO, Per Hellsund.

“I was impressed with Cybrexa’s revolutionary technology and excellent leadership team,” Dr. Paralkar said. “The team has had multiple past successes and I am excited to bring this technology to market.”

Dr. Paralkar has more than 20 years of experience in drug development, and brings extensive drug discovery expertise and knowledge to the team. He joins Cybrexa from Karos, Inc., where he was recently the chief scientific officer. Prior to that, he held numerous senior level positions at Pfizer. Vishwas is a very experienced drug developer responsible for submitting 8 INDs (including both small and large molecules) and one drug approval.

Hellsund commented, “We are very pleased to have Vishwas join our team. We are confident that his leadership and breadth of drug development experience will enable us to move our technology from the research stage into the clinic.”

Cybrexa is a privately funded biotechnology company dedicated to developing an entirely new class of small molecule DNA repair inhibitors and DNA damaging agents (TSDs) that directly target the tumor microenvironment. This approach will both improve the efficacy while at the same time reduce toxicity of existing cancer drugs. The Company has made significant progress since it’s inception and now has several drug candidates that are being run through its in vitro and in vivo screening platform. The objective is to have at least one of it’s TSDs ready for a phase I clinical trial within two years.

About Cybrexa:

Cybrexa was founded by successful entrepreneurs Hellsund, Kevin Didden and Kevin Rakin, who most recently built and successfully exited Cyvek, Inc. Hellsund serves as the President and CEO, and Didden and Rakin serve as board members. Additional members of the founding team include Ranjit Bindra, M.D., Ph.D., and Peter Glazer, M.D., Ph.D., from the Yale School of Medicine. Bindra and Glazer are both physician-scientists and world-renowned experts in DNA repair. Their work has been published in numerous high-impact journals, including Science, Nature, and Science Translational Medicine.

For more information about Cybrexa, please call 860-717-2731 or visit us on the web at http://www.cybrexa.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Per Hellsund
Cybrexa
+1 860-799-1517
Email >
Visit website